Discover the latest CEPI news
Keep up-to-date on the latest announcements and updates from CEPI and our global partners.
Blog
CEPI and World Bank Group partner to strengthen sustainable vaccine manufacturing in ASEAN
CEPI and the World Bank Group (WBG), together with AVPN and others, have launched a partnership to strengthen vaccine manufacturing across ASEAN, supporting the ASEAN Vaccine Security and Self-Reliance Initiative (AVSSR).
_0.webp)
CEPI
First participants vaccinated with Oxford's CEPI-backed Lassa shot in Ghana
Statement
Final preparations underway for pivotal Phase 2/3 Bundibugyo vaccine trial
Blog
Tracking Lassa fever: Where are we up to?
Impact story
How AI and a 'Nanoball' vaccine could fight deadly viruses in Japan and beyond
News
UK rabies vaccine trial could also unlock protection against Disease X
_Andreas%20Kravik%20(Norway)_Chris%20Elmore%20(UK)_Abnet%20Zeleke%20(Ethiopia)_Mamadou%20Ndiaye%20(Senegal)_Sept%2021_2026.webp)
News
Ethiopia, Norway and UK commit US$240 million to CEPI’s global plan to tackle epidemic and pandemic threats
News
New research set to strengthen epidemic intelligence and modelling for Bundibugyo virus response
News
India ramps up Disease X preparedness with $8.9 million funding boost for its freezer-free RNA vaccine
CEPI
Indonesia steps up Southeast Asia’s outbreak preparedness with pandemic simulation exercise
.webp)
News
African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials
Blog
100 days into the Bundibugyo emergency, unprecedented speed is still not enough
%20.webp)
News
New studies to test whether existing Ebola vaccines can generate immune responses to Bundibugyo ebolavirus
Explainer
CEPI 3.0 cross-cutting themes explained: Biosecurity
News
CEPI Board appoints Ibrahim Abubakar as new Chief Executive Officer
News
CEPI’s Principles for Responding to Outbreaks
News
African Institutions' Readiness to Conduct Phase 1 Bundibugyo Vaccine Trials
Impact story
How vaccine trials in Congo could help protect mothers and children from Mpox
News
Moderna’s Bundibugyo ebolavirus vaccine candidate enters first human trial, backed by CEPI
News
Hilleman Laboratories to develop and produce CEPI-backed Bundibugyo ebolavirus vaccine doses for clinical trials
Explainer
CEPI 3.0 explained: Networks
News
Smaller COVID-19 vaccine booster doses match full-dose protection for up to two years
.webp)
News
CEPI-backed Bundibugyo ebolavirus vaccine trial launched by Oxford
Blog
Chukwuemeka Oguanuo: My Fellowship at CEPI
Blog
Bundibugyo and the 100 Days Mission: Preparedness, Readiness and Response
Blog
New models of health-defence collaboration: a shared plan to achieve the 100 Days Mission
News
New experts appointed to CEPI’s Scientific Advisory Committee
Blog
The lab scientists banding together to test new outbreak-busting vaccines
Explainer
CEPI 3.0 explained: Platform technologies
Statement
CEPI statement: G7 Leaders' call for a coordinated response to the Bundibugyo ebola outbreak
News
U.S. Department of State commits $50 million to CEPI to fast-track Bundibugyo virus medical countermeasures
Blog
Biosecurity-by-design for CEPI’s Pandemic Preparedness Engine
Impact story
Outbreak ready, research ready: strengthening West Africa’s research ecosystem
Speech
The 100-Day Imperative: pandemic preparedness, AI-driven threats, and the case for a new global architecture
News
CEPI awards Public Health Vaccines US$1.9m to accelerate Bundibugyo ebolavirus vaccine
Blog
Three vaccine designs in the race to contain Bundibugyo Ebola
Blog
From market failure to epidemic preparedness: the race for a Bundibugyo Ebola vaccine
News
CEPI funds next phase of nanoparticle vaccine platform to support rapid outbreak response
News
CEPI fast-tracks three Bundibugyo ebolavirus vaccine candidates
News
CEPI Statement: CEPI’s response to epidemic of Ebola Disease caused by Bundibugyo virus
News
